Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A genome screen for multiple sclerosis in Italian families.
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis
Calcitriol Modulates the CD46 Pathway in T Cells.
Gilenya prescribing information
Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis.
Clinical overview of the seizure risk of dalfampridine.
Amyloid precursor protein at node of Ranvier modulates nodal formation.
Rituximab: Don't Count It Out as MS Treatment
Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.
Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg
Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: inference for multiple sclerosis.
Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters.
Patients with migraine do not have MRI-visible cortical lesions.
Interference with RhoA-ROCK Signaling Mechanism in Autoreactive CD4(+) T Cells Enhances the Bioavailability of 1,25-Dihydroxyvitamin D(3) in Experimental Autoimmune Encephalomyelitis.
Keystone Symposium on Growing to Extremes: Cell Biology and Pathology of Axons
Narcolepsy with cataplexy and comorbid immunopathological diseases.
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.

Pages